Lomond Therapeutics Announces Upcoming Presentation
Lomond Therapeutics, a proud subsidiary of Eilean Therapeutics LLC, has exciting news to share with the biopharmaceutical community. The company is gearing up for an important moment as they prepare for a poster presentation at the forthcoming American Society of Hematology (ASH) Annual Meeting. This prestigious event is set to take place in December, and Lomond Therapeutics will showcase their significant research on Lomonitinib, a selective pan-FLT3/IRAK4 inhibitor.
Understanding Lomonitinib's Impact
Lomonitinib is making waves in the world of oncology due to its targeted action against clinically relevant FLT3 mutations and potential escape pathways. A recently published abstract will focus on a Phase 1 trial that investigates the safety, pharmacokinetics, and pharmacodynamics of this promising drug. The poster’s title, "A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134)", captures the essence of a rigorous and compelling study.
Details of the Presentation Session
The poster will be part of a session titled 604, focusing on Molecular Pharmacology and Drug Resistance in Myeloid Neoplasms. Interested attendees can look for Lomond's presentation on a Saturday in December. The session promises to be insightful, as healthcare professionals and researchers gather to explore advancements in cancer treatment and drug development.
About Eilean Therapeutics LLC
Eilean Therapeutics is a company driven by innovation in biopharmaceuticals. Co-founded by a dynamic team including Orbimed and Torrey Pines Investment alongside Dr. John C. Byrd, Eilean is dedicated to discovering and developing pioneering small molecule inhibitors. Their focus is particularly on targeting escape mutations found in hematologic and solid cancers. By leveraging a proprietary hybrid AI platform, Eilean Therapeutics aims to design therapies that not only treat but also transform patient outcomes.
Pioneering New Treatments
With a commitment to excellence, Eilean Therapeutics seeks to establish itself as a frontrunner in the field of breakthrough medications. Their strategic partnerships and advanced technology position them as leaders in addressing the complexities of cancer treatment. The goal remains clear: to offer patients the best possible therapeutic options that maximize clinical benefits.
Media Contact Information
For anyone looking for further information about this exciting research presentation and the revolutionary work being done at Lomond Therapeutics, media inquiries can be directed to Amy Burd, the Chief Scientific Officer. Although specific contact details are reserved to maintain privacy, Lomond Therapeutics encourages interested parties to reach out for inquiries.
Frequently Asked Questions
What is Lomonitinib?
Lomonitinib is a novel drug developed by Lomond Therapeutics that acts as a pan-FLT3/IRAK4 inhibitor, targeting significant mutations associated with cancers.
When will the ASH Annual Meeting take place?
The ASH Annual Meeting is scheduled for December, with Lomond Therapeutics presenting their work during this important event.
Who is behind Eilean Therapeutics?
Eilean Therapeutics is co-founded by Orbimed, Torrey Pines Investment, and prominent oncologist Dr. John C. Byrd.
What is the main focus of Eilean Therapeutics?
The main focus is on discovering first-in-class inhibitors that are effective against escape mutations in both hematologic and solid tumors.
How can I find more information about Lomond Therapeutics?
Individuals can learn more by reaching out through appropriate channels or looking for official updates from Eilean Therapeutics.
